Compare GoPro Inc (GPRO) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Eli Lilly And Co — how do they compare? GoPro Inc trades at $0.69 (market cap $122.03M), while Eli Lilly And Co trades at $1,187.2 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 8440.5× GoPro Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| GPRO | LLY | |
|---|---|---|
Market Cap | $122.03M | $1.03T |
Sector | Technology | Health |
52-Week High | $2.88 | $1.24K |
52-Week Low | $0.64 | $625.65 |
Enterprise Value | $169.98M | $1.07T |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.6978, down 1.86% on the day, reflecting persistent bearish sentiment amid financial distress. The stock shows a negative technical trend with recent earnings misses and declining revenues. The company is undergoing a strategic review for a potential sale or merger, with the CEO providing $20 million in financing to support operations. Valuation ratios like P/E of 4.56 and P/S of 0.18 appear low, but profitability remains deeply negative with a net income margin of -20.7% and ROE of -236.05%.
The outlook is highly speculative, hinging on the success of the strategic review; a sale could unlock value, but ongoing cash burn and competitive pressures pose significant risks. Investors face a binary outcome: potential upside from a strategic transaction versus substantial downside if the company fails to stabilize.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
